What is Radiopharm Theranostics Limited (RADX)?

Radiopharm Theranostics Limited (RADX) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of RADX?

The current price of RADX is $1.08. Prices are updated in real time on Stocks360.

What is RADX's price-to-earnings (PE) ratio?

RADX's trailing twelve-month PE ratio is -0.32, based on current price and earnings per share data available on Stocks360.

What is RADX's market capitalization?

RADX's market capitalization is $1,391,256.00, placing it in the small-cap tier.

Radiopharm Theranostics Limited (RADX)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$1.08

Market Cap

$1.39M

PE (TTM)

-0.32

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.80

Day Range

$1.08 – $1.16

52-wk Range

$0.90 – $16.25

Avg Volume

N/A

Volume

8.37K

Radiopharm Theranostics Limited (RADX) is a publicly traded company in the Healthcare sector. Latest price: $1.08. Market cap $1.39M. Trailing PE -0.32. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 6 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-31 · $5.26 2026-10-30 · $1.08 (-79.47%)

Earnings

Most Recent

Aug 28, 2026

EPS $-1.20 vs est. $-1.67

Beat by $0.48

Next Earnings

Feb 26, 2027

EPS estimate $-1.05

Proprietary Signals

Signal snapshot temporarily unavailable.

About Radiopharm Theranostics Limited

Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating products for both diagnostic imaging and therapeutic intervention across a spectrum of challenging medical conditions. The company's diverse pipeline features: RAD 204, designed to target PD-L1 for non-small cell lung cancer; RAD 202, aimed at HER2 for breast cancer and other solid tumor types; and two avß6 integrin-targeting agents, RAD 301 (a diagnostic tool for pancreatic ductal adenocarcinoma) and RAD 302 (a therapeutic agent for various cancers). Other significant developments include RAD 101 and RAD 102 for brain metastases, RAD 402 for advanced prostate cancer, and RV01 for multiple solid tumors. To accelerate the clinical progression of its radiopharmaceutical assets, Radiopharm Theranostics maintains a strategic partnership with Lantheus Holdings, Inc.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.32×
P/S (TTM)	4.27×
P/B	0.71×
P/FCF (TTM)	-0.52×
EV / EBITDA	-0.11×
EV / Sales	2.78×
Earnings Yield	-313.08%
Free Cash Flow Yield	-191.74%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$7.69M
Revenue (TTM)	$2.77M
Net Income (TTM)	-$37.02M
Free Cash Flow (TTM)	-$58.10M
Net Debt	-$4.14M
Working Capital	$3.03M
Gross Margin	-39.41%
Operating Margin	-2545.78%
Net Margin	-1992.46%
Return on Equity	-144.24%
Return on Invested Capital	-158.08%